BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

825 related articles for article (PubMed ID: 11604501)

  • 1. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis.
    Eischen CM; Roussel MF; Korsmeyer SJ; Cleveland JL
    Mol Cell Biol; 2001 Nov; 21(22):7653-62. PubMed ID: 11604501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.
    Eischen CM; Weber JD; Roussel MF; Sherr CJ; Cleveland JL
    Genes Dev; 1999 Oct; 13(20):2658-69. PubMed ID: 10541552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development.
    Eischen CM; Alt JR; Wang P
    Oncogene; 2004 Nov; 23(55):8931-40. PubMed ID: 15467748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis.
    Alt JR; Greiner TC; Cleveland JL; Eischen CM
    EMBO J; 2003 Mar; 22(6):1442-50. PubMed ID: 12628936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
    Yu D; Thomas-Tikhonenko A
    Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MIF loss impairs Myc-induced lymphomagenesis.
    Talos F; Mena P; Fingerle-Rowson G; Moll U; Petrenko O
    Cell Death Differ; 2005 Oct; 12(10):1319-28. PubMed ID: 15947793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated Mdm2 expression induces chromosomal instability and confers a survival and growth advantage to B cells.
    Wang P; Lushnikova T; Odvody J; Greiner TC; Jones SN; Eischen CM
    Oncogene; 2008 Mar; 27(11):1590-8. PubMed ID: 17828300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenovirus-mediated overexpression of p14(ARF) induces p53 and Bax-independent apoptosis.
    Hemmati PG; Gillissen B; von Haefen C; Wendt J; Stärck L; Güner D; Dörken B; Daniel PT
    Oncogene; 2002 May; 21(20):3149-61. PubMed ID: 12082630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival and death of prelymphomatous B-cells from N-myc/bcl-2 double transgenic mice correlates with the regulation of intracellular Ca2+ fluxes.
    Zörnig M; Busch G; Beneke R; Gulbins E; Lang F; Ma A; Korsmeyer S; Möröy T
    Oncogene; 1995 Nov; 11(10):2165-74. PubMed ID: 7478538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways.
    Meng X; Carlson NR; Dong J; Zhang Y
    Oncogene; 2015 Nov; 34(46):5709-17. PubMed ID: 25823025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bax accelerates tumorigenesis in p53-deficient mice.
    Knudson CM; Johnson GM; Lin Y; Korsmeyer SJ
    Cancer Res; 2001 Jan; 61(2):659-65. PubMed ID: 11212265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential synergism of Bim with p53 in mice with Myc‑induced lymphoma in a mouse lymphoma model.
    Shang Q; Zhang D; Guo C; Lin Q; Guo Z; Deng C
    Mol Med Rep; 2012 Jun; 5(6):1401-8. PubMed ID: 22446994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apoptosis triggered by Myc-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis.
    Eischen CM; Woo D; Roussel MF; Cleveland JL
    Mol Cell Biol; 2001 Aug; 21(15):5063-70. PubMed ID: 11438662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
    Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
    Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of Bax alters tumor spectrum and tumor numbers in ARF-deficient mice.
    Eischen CM; Rehg JE; Korsmeyer SJ; Cleveland JL
    Cancer Res; 2002 Apr; 62(7):2184-91. PubMed ID: 11929842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation.
    Nilsson JA; Keller UB; Baudino TA; Yang C; Norton S; Old JA; Nilsson LM; Neale G; Kramer DL; Porter CW; Cleveland JL
    Cancer Cell; 2005 May; 7(5):433-44. PubMed ID: 15894264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.
    Hemann MT; Bric A; Teruya-Feldstein J; Herbst A; Nilsson JA; Cordon-Cardo C; Cleveland JL; Tansey WP; Lowe SW
    Nature; 2005 Aug; 436(7052):807-11. PubMed ID: 16094360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory elements in the immunoglobulin heavy chain gene 3'-enhancers induce c-myc deregulation and lymphomagenesis in murine B cells.
    Wang J; Boxer LM
    J Biol Chem; 2005 Apr; 280(13):12766-73. PubMed ID: 15687498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IBTK contributes to B-cell lymphomagenesis in Eμ-myc transgenic mice conferring resistance to apoptosis.
    Vecchio E; Golino G; Pisano A; Albano F; Falcone C; Ceglia S; Iaccino E; Mimmi S; Fiume G; Giurato G; Britti D; Scala G; Quinto I
    Cell Death Dis; 2019 Apr; 10(4):320. PubMed ID: 30975981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis.
    Michalak EM; Jansen ES; Happo L; Cragg MS; Tai L; Smyth GK; Strasser A; Adams JM; Scott CL
    Cell Death Differ; 2009 May; 16(5):684-96. PubMed ID: 19148184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.